星空体育官方入口网站网址大全-登录入口官网

#CLL#

2篇内容 | 1311人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2217821, encodeId=d174221e821af, content=<a href='/topic/show?id=714948524e' target=_blank style='color:#2F92EE;'>#CLL#</a> <a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞白血病#</a>, objectTitle=柳叶刀重磅综述：慢性淋巴细胞白血病, objectType=article, longId=836855, objectId=e05283685549, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301017/1697523836362_2570354.jpg, objectUrl=/article/show_article.do?id=e05283685549, replyNumber=0, likeNumber=5, createdTime=2024-07-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e05283685549, moduleTitle=柳叶刀重磅综述：慢性淋巴细胞白血病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e05283685549)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211584, encodeId=3066221158434, content=<a href='/topic/show?id=714948524e' target=_blank style='color:#2F92EE;'>#CLL#</a> <a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞白血病#</a>, objectTitle=【Blood】靶向治疗时代，CLL是否需要新的预后评分？, objectType=article, longId=831577, objectId=874c8315e7b6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240625/1719280828252_5579292.jpg, objectUrl=/article/show_article.do?id=874c8315e7b6, replyNumber=0, likeNumber=0, createdTime=2024-06-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=874c8315e7b6, moduleTitle=【Blood】靶向治疗时代，CLL是否需要新的预后评分？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=874c8315e7b6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2201780, encodeId=7a972201e80c9, content=<a href='/topic/show?id=714948524e' target=_blank style='color:#2F92EE;'>#CLL#</a> <a href='/topic/show?id=787741e439d' target=_blank style='color:#2F92EE;'>#基因异常#</a> <a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞白血病#</a>, objectTitle=【BJH】无17p缺失、免疫化疗的一线CLL中基因异常的预后影响, objectType=article, longId=824271, objectId=a57f8242e16b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/hospital-staff-at-work-PGMH47J.jpg, objectUrl=/article/show_article.do?id=a57f8242e16b, replyNumber=0, likeNumber=58, createdTime=2024-05-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a57f8242e16b, moduleTitle=【BJH】无17p缺失、免疫化疗的一线CLL中基因异常的预后影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a57f8242e16b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2106417, encodeId=1812210641ebb, content=<a href='/topic/show?id=2c90650e5b1' target=_blank style='color:#2F92EE;'>#泽布替尼#</a>头对头比较<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>对<a href='/topic/show?id=714948524e' target=_blank style='color:#2F92EE;'>#CLL#</a>的疗效与安全性, objectTitle=NEJM：泽布替尼头对头比较伊布替尼对CLL的疗效与安全性, objectType=article, longId=752082, objectId=5788e520825b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/6c380a32a671489d85dc7939d79a631d.jpg, objectUrl=/article/show_article.do?id=5788e520825b, replyNumber=0, likeNumber=78, createdTime=2022-12-17, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5788e520825b, moduleTitle=NEJM：泽布替尼头对头比较伊布替尼对CLL的疗效与安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5788e520825b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=906086, encodeId=e7599060869a, content=LOXO-305具有令人难以置信的安全性和疗效。emmm，期待吧<a href='/topic/show?id=714948524e' target=_blank style='color:#2F92EE;'>#CLL#</a>, objectTitle=ASH 2020：礼来的LOXO-305在复发难治CLL/SLL中显示62％的缓解率, objectType=article, longId=204326, objectId=d24d20432640, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020128/1607419470121_5295902.jpeg, objectUrl=/article/show_article.do?id=d24d20432640, replyNumber=0, likeNumber=153, createdTime=2020-12-08, rootId=0, userName=Psycho.Dr Du, userId=a8fb2299762, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d24d20432640, moduleTitle=ASH 2020：礼来的LOXO-305在复发难治CLL/SLL中显示62％的缓解率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d24d20432640)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CLL

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#CLL# #慢性淋巴细胞白血病#

柳叶刀重磅综述：慢性淋巴细胞白血病

2024-07-31发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#CLL# #慢性淋巴细胞白血病#

【Blood】靶向治疗时代，CLL是否需要新的预后评分？

2024-06-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#CLL# #基因异常# #慢性淋巴细胞白血病#

【BJH】无17p缺失、免疫化疗的一线CLL中基因异常的预后影响

2024-05-04发表于上海

lifestar (审核中...)

前往app查看评论内容

#泽布替尼#头对头比较#伊布替尼#对#CLL#的疗效与安全性

NEJM：泽布替尼头对头比较伊布替尼对CLL的疗效与安全性

2022-12-17发表于上海

Psycho.Dr Du (审核中...)

前往app查看评论内容

LOXO-305具有令人难以置信的安全性和疗效。emmm，期待吧#CLL#

ASH 2020：礼来的LOXO-305在复发难治CLL/SLL中显示62％的缓解率

2020-12-08

科室
- - 订阅+
  - 更多科室
工具
服务